Item 7.01 Regulation FD Disclosure.
Aquestive Therapeutics, Inc. (the “Company”) is furnishing this Current Report
on Form 8-K in connection with the disclosure of information, in the form of
investor presentations, to be given at meetings with institutional investors,
analysts and others. This information may be amended or updated at any time and
from time to time through another Current Report on Form 8-K, a later company
filing or other means. A copy of the Company’s investor presentations are
attached hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report
on Form 8-K and incorporated into this Item 7.01 by reference and replaces in
its entirety all prior investor presentations filed by the Company. The investor
presentations are available on the Company’s website located at
http://www.aquestive.com, although the Company reserves the right to discontinue that
availability at any time.
The information in this Item 7.01 (including Exhibits 99.1 and 99.2) shall not
be deemed to be “filed” for purposes of, or otherwise subject to the liabilities
of, Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall it be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
Exhibit Description
Number
99.1 Aquestive Therapeutics Corporate Presentation dated August 2022
99.2 Aquestive Therapeutics Q2 2022 Earnings Supplemental Materials dated August
2022
© Edgar Online, source Glimpses
postbrexitcompliance.com 